HSIC vs BTSG vs GRDN Stock Comparison

Henry Schein, BrightSpring Health Services and Guardian Pharmacy Services Prices as of Nov 13, 2026 Peers: Industry group
HSIC Henry Schein Inc
$86.22 +0.8% 1M +17.6% 1Y
Market cap
$9.51B
P/E
22.6x
Revenue (TTM)
$13.73B
Div. yield
0.00%
Drug Distribution Healthcare
3 wins

Head to Head

10 decided of 12

BrightSpring Health Services leads on 5 of the 12 questions below (BrightSpring Health Services 5, Henry Schein 3, Guardian Pharmacy Services 2). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionHSICBTSGGRDNLeader
Larger companyMarket capitalisation $9.51B $14.74B $3.13B BTSG
Cheaper on earningsLower P/E, profitable companies only 22.6x 35.9x 41.9x HSIC
Cheaper on forward earningsLower price / next fiscal year consensus EPS 14.6x 38.9x 37.5x HSIC
Faster revenue growthRevenue growth, trailing twelve months +6.2% +26.0% +4.9% BTSG
More profitableNet margin, trailing twelve months 3.1% 2.7% 5.1% GRDN
Better return on capitalReturn on invested capital 7.3% 10.0% — BTSG
Less leveragedLower net debt / EBITDA 3.2x 2.1x — BTSG
Higher dividend yieldTrailing dividend yield 0.00% 0.00% — –
Better 1-year returnPrice return, last 12 months +17.6% +124.3% +62.6% BTSG
Better 5-year returnAnnualised price return, 5 years +1.7%/yr — — –
Less volatileAnnualised volatility, 1 year 25.2% 45.8% 42.4% HSIC
Higher overall scoreMean of the five percentile scores vs peers 57/100 65/100 71/100 GRDN

Percentile Scorecard

HSICBTSGGRDN

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisHSICBTSGGRDN
Valuation 46 #15 of 27 57 #43 of 99 23 #21 of 27
Growth 48 #14 of 26 93 #7 of 89 76 #7 of 26
Profitability 76 #7 of 26 64 #34 of 92 96 #2 of 26
Financial Health 20 #21 of 26 47 #55 of 103 88 #4 of 26
Shareholder Returns 94 #2 of 18 66 #22 of 63 –
Overall 57 65 71
  • HSIC ranked among 27 companies in Healthcare Payers and Distributors
  • BTSG ranked among 103 companies in Healthcare Providers
  • GRDN ranked among 27 companies in Healthcare Payers and Distributors

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodHSICBTSGGRDNSPY
1 month +0.8%+12.4%+21.9% -2.0%
3 months -4.0%+15.4%+28.7% -2.8%
6 months +18.6%+23.0%+35.1% +2.0%
Year to date +14.1%+90.1%+64.4% +10.6%
1 year +17.6%+124.3%+62.6% +12.2%
3 years +25.1%—— +68.1%
3 years, per year +7.8%—— +18.9%
5 years +8.8%—— +61.4%
5 years, per year +1.7%—— +10.1%
10 years +40.3%—— +248.5%
10 years, per year +3.4%—— +13.3%

Risk

MeasureHSICBTSGGRDNSPY
Volatility, 1Y 25.2%45.8%42.4% 13.6%
Downside volatility, 1Y 25.4%50.7%39.1% 13.9%
Beta vs S&P 500, 1Y 0.631.080.71 1.00
Return / volatility, 1Y 0.702.711.48 0.90
Max drawdown, 5Y -32.7%-35.6%-27.2% -25.4%
From 52-week high -5.1%-2.3%-1.1% -3.2%
52-week high $90.86$72.91$50.01 $779.14
52-week low $68.99$31.36$27.03 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleHSICBTSGGRDN
P/E now vs peer median 22.8xmedian 25.2x 35.9xmedian 22.4x 41.9xmedian 25.2x
P/S now vs peer median 0.7xmedian 0.4x 0.9xmedian 1.3x 2.2xmedian 0.4x
EV/EBITDA now vs peer median 12.4xmedian 14.5x 22.6xmedian 14.2x 25.6xmedian 14.5x
P/FCF now vs peer median 17.0xmedian 16.5x 28.8xmedian 19.0x 40.0xmedian 16.5x
P/B now vs peer median 2.5xmedian 2.7x 6.5xmedian 2.6x 11.2xmedian 2.7x
PEG now vs peer median 6.74median 1.72 —median 0.84 —median 1.72

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsHSICBTSGGRDN
Revenue $13.73B $15.25B $1.46B
Gross profit $4.34B $1.91B $327.08M
Operating income $709.00M $520.43M $94.14M
Net income $443.00M $410.46M $74.77M
Free cash flow $559.00M $492.41M $78.35M
EPS (diluted) $3.74 $1.86 $1.17
Cash & equivalents $184.00M $717.84M $119.66M
Total debt $3.52B $2.18B –
Shares (diluted) 112.54M 220.23M 63.92M
Enterprise value $9.33B $11.61B $2.81B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricHSICBTSGGRDN
P/E 22.8x 35.9x 41.9x
P/FCF 17.0x 28.8x 40.0x
P/Operating cash flow 13.9x 23.5x 27.5x
P/S 0.7x 0.9x 2.2x
P/B 2.5x 6.5x 11.2x
P/Tangible book 3.3x 8.4x 12.1x
EV/EBITDA 12.4x 22.6x 25.6x
EV/EBIT 18.2x 30.0x 32.0x
EV/Revenue 0.9x 1.0x 2.1x
EV/FCF 23.0x 31.7x 38.5x
EV/Operating cash flow 18.7x 25.9x 26.4x
PEG (3Y EPS CAGR) 6.74 – –

Growth

14 metrics
MetricHSICBTSGGRDN
Revenue growth (1Y) 6.2% 26.0% 4.9%
Revenue CAGR (3Y) 2.7% – –
Gross profit growth (1Y) 7.5% 32.0% 19.2%
Gross profit CAGR (3Y) 3.3% – –
Operating income growth (1Y) 9.9% 114.5% 60.4%
Operating income CAGR (3Y) 3.0% – –
Net income growth (1Y) 7.5% 219.3% 85.8%
Net income CAGR (3Y) -2.0% – –
EPS growth (1Y) 15.8% 213.4% 84.4%
EPS CAGR (3Y) 3.4% – –
Operating cash flow growth (1Y) 28.4% 72.6% 29.6%
Operating cash flow CAGR (3Y) -4.4% – –
Free cash flow growth (1Y) 38.7% 78.3% 18.9%
Free cash flow CAGR (3Y) -4.9% – –

Profitability

14 metrics
MetricHSICBTSGGRDN
Gross margin 31.6% 12.5% 22.4%
EBITDA margin 7.6% 4.5% 8.1%
Operating margin 5.2% 3.4% 6.5%
Pretax margin 4.2% 2.5% 7.2%
Net margin 3.1% 2.7% 5.1%
FCF margin 4.1% 3.2% 5.4%
Operating cash flow margin 5.0% 4.0% 7.8%
Return on equity 11.6% 19.4% 28.3%
Return on assets 3.9% 6.7% 16.3%
Return on invested capital 7.3% 10.0% –
Return on capital employed 9.0% 11.8% 32.6%
Asset turnover 1.2x 2.5x 3.1x
Cash conversion (OCF / net income) 1.6x 1.5x 1.5x
Stock comp / revenue 0.3% 0.4% 0.6%

Financial Health

11 metrics
MetricHSICBTSGGRDN
Debt / assets 30.6% 34.8% –
Debt / equity 0.9x 1.0x –
Net debt / EBITDA 3.2x 2.1x –
Debt / FCF 6.3x 4.4x –
Liabilities / assets 66.8% 65.3% 43.1%
Equity / assets 33.2% 34.7% 56.9%
Interest coverage 4.3x 3.6x 145.3x
Current ratio 1.3x 1.6x 1.6x
Quick ratio 0.6x 1.2x 1.3x
Cash ratio 0.1x 0.4x 0.7x
Altman Z-score 2.65 5.02 13.09

Shareholder Returns

7 metrics
MetricHSICBTSGGRDN
Dividend yield – – –
Net buyback yield 6.8% 0.5% –
Shareholder yield 6.8% 0.5% –
Payout ratio (earnings) 6.8% – –
Payout ratio (FCF) 5.4% – –
Dividend growth (1Y) – – –
Dividend CAGR (3Y) – – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusHSICBTSGGRDN
Forward P/E 14.6xFY2026 38.9xFY2026 37.5xFY2026
EPS, next fiscal year $5.89FY2026 $1.83FY2026 $1.32FY2026
EPS growth, next FY +18.5%FY2026 +83.0%FY2026 +23.4%FY2026
EPS growth, the year after +5.9% +43.7% +18.9%
Revenue, next fiscal year $13.36BFY2026 $16.69BFY2026 $1.42BFY2026
Revenue growth, next FY +1.3%FY2026 +29.3%FY2026 -2.2%FY2026
Revenue growth, the year after +4.6% +3.1% +2.7%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersHSICBTSGGRDN
Held by institutions 100.0% 100.0% 58.6%
Institutions holding 566 423 189
Change in shares held, QoQ +2.1% -0.7% +3.8%
Institutions buying 244 309 109
Institutions selling 217 83 54
Buyers to sellers 1.12 3.72 2.02

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

HSICBTSGGRDN
HSIC 1.00 0.18 0.17
BTSG 0.18 1.00 0.36
GRDN 0.17 0.36 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, HSIC, BTSG and GRDN?

BrightSpring Health Services (BTSG) is the largest by market capitalisation: Henry Schein (HSIC) $9.51B, BrightSpring Health Services (BTSG) $14.74B, Guardian Pharmacy Services (GRDN) $3.13B.

Which stock is cheaper, HSIC, BTSG and GRDN?

Henry Schein (HSIC) trades on the lowest price-to-earnings ratio (Henry Schein (HSIC) 22.6x, BrightSpring Health Services (BTSG) 35.9x, Guardian Pharmacy Services (GRDN) 41.9x). On next year's consensus earnings, Henry Schein (HSIC) is cheapest (Henry Schein (HSIC) 14.6x, BrightSpring Health Services (BTSG) 38.9x, Guardian Pharmacy Services (GRDN) 37.5x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

BrightSpring Health Services (BTSG) grew revenue fastest over the trailing twelve months: Henry Schein (HSIC) +6.2%, BrightSpring Health Services (BTSG) +26.0%, Guardian Pharmacy Services (GRDN) +4.9%.

Which company is more profitable?

Guardian Pharmacy Services (GRDN) has the highest net margin (Henry Schein (HSIC) 3.1%, BrightSpring Health Services (BTSG) 2.7%, Guardian Pharmacy Services (GRDN) 5.1%). On return on invested capital, BrightSpring Health Services (BTSG) leads (Henry Schein (HSIC) 7.3%, BrightSpring Health Services (BTSG) 10.0%).

Which stock has performed better?

Over the past year BrightSpring Health Services (BTSG) returned the most: Henry Schein (HSIC) +17.6%, BrightSpring Health Services (BTSG) +124.3%, Guardian Pharmacy Services (GRDN) +62.6%. Returns are price only, before dividends.

Which stock is riskier?

By one-year price volatility, Henry Schein (HSIC) has been the steadiest (Henry Schein (HSIC) 25.2%, BrightSpring Health Services (BTSG) 45.8%, Guardian Pharmacy Services (GRDN) 42.4%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, HSIC, BTSG and GRDN?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, BrightSpring Health Services (BTSG) leads on 5. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.